Shots:
- Bavarian Nordic has reported topline P-II trial results evaluating two standard doses of the MVA-BN mpox/smallpox vaccine in 460 participants, incl. children (2–11 yrs) & adults (18–50 yrs) across 2 cohorts in the DRC & Uganda
- In the trial, 227 children among 451 evaluable subjects showed a non-inferior immune response to adults (n=224) 2wks. post-second dose, with the highest responses in children aged 2–5yrs.; pediatric immunity was 2.5 times higher than that of adults, with comparable safety
- Bavarian Nordic plans to submit the study data to the EMA in 2026 to support extended use of the vaccine in children (≥2yrs.), pending the final results
Ref: Bavarian Nordic | Image: Bavarian Nordic| Press Release
Related News:- Bavarian Nordic Reports the Health Canada’s NDS Acceptance of CHIKV VLP to Prevent Chikungunya
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
